Abstract
The purpose of the work was to study the range and volume of consumption of diuretics on the pharmaceutical market of Ukraine in 2019-2021. Materials and methods. Indications for the use of diuretics in medicine and sports, as well as the results of monitoring their consumption on the pharmaceutical market of Ukraine in the period from 2019 to 2021 are given in the article. The analysis of the range of diuretic drugs on the pharmaceutical market of Ukraine was carried out according to the information and search system “Pharmstandard” of the “Morion” company. Monitoring of the volume and structure of drug consumption was carried out using the ATС/DDD methodology. Results and discussion. The results of the research showed that diuretic drugs on the pharmaceutical market of Ukraine were represented by four pharmacological subgroups of drugs: thiazide and thiazide-like diuretics, herbal drugs, loop and potassium-sparing diuretics. The number of available International Non-Proprietary Names for 2019-2021 was 11, and trade names – from 110 to 116. The correlation between foreign and domestic manufacturers was: 42-51% and 49-58%, respectively. Torasemide took the first place among the leaders on the market of Ukraine in terms of the number of trade names – from 38 to 39 trade names, because it is more effective, with a pharmacological effect that exceeds furosemide by 2-8 times. Preparations of plant origin took the second place – from 21 to 23 trade names. Indapamide was in the third place – 14 trade names. The total consumption of diuretics for 2019-2021 was 15.83 DIDs in 2019, 15.98 DIDs in 2020 and 16.36 DIDs in 2021. Conclusion. The results of the monitoring showed that the leaders in terms of consumption on the market of Ukraine were the loop diuretic furosemide (4.79-5.24 DIDs) and the potassium-sparing diuretic spironolactone (3.07-3.60 DIDs). In our opinion, the high levels of consumption of these diuretics are due to such a criterion as availability, as well as their presence in the list of drugs for the treatment of cardiovascular diseases, which are included in the Government program “Affordable Drugs” and are reimbursed at the expense of the state (partially at the expense of patients). In the future, in this direction, it is planned to investigate the safety of the use of diuretic drugs, both in patients and in athletes. It will also be necessary to monitor the adverse reactions of these drugs in order to identify serious adverse reactions that may threaten human life and to develop measures to prevent the development of undesirable consequences
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
